Pamela Esposito - Jul 10, 2023 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Role
Chief Business Officer
Signature
/s/ Shawn Glidden, attorney-in-fact
Stock symbol
REPL
Transactions as of
Jul 10, 2023
Transactions value $
-$304,541
Form type
4
Date filed
7/11/2023, 09:00 PM
Previous filing
Jun 20, 2023
Next filing
Aug 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REPL Common Stock Options Exercise $49.5K +15K +5.69% $3.30* 278K Jul 10, 2023 Direct
transaction REPL Common Stock Options Exercise $77.5K +5K +1.8% $15.50 283K Jul 10, 2023 Direct
transaction REPL Common Stock Sale -$388K -17.9K -6.32% $21.63 266K Jul 10, 2023 Direct F1, F2
transaction REPL Common Stock Sale -$43.9K -2.08K -0.78% $21.12 263K Jul 10, 2023 Direct F1, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REPL Employee Stock Option (right to buy) Options Exercise $0 -15K -12.33% $0.00 107K Jul 10, 2023 Common Stock 15K $3.30 Direct F5
transaction REPL Employee Stock Option (right to buy) Options Exercise $0 -5K -10.93% $0.00 40.8K Jul 10, 2023 Common Stock 5K $15.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
F2 The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.18 to $22.17. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.09 to $21.17. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Following the sales reported on this Form 4, the reporting person continues to beneficially own 263,436 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 517,227 shares of the Issuer's common stock, 395,314 of which are exercisable as of the date hereof.
F5 The reporting person was granted an option to purchase 134,281 shares of the Issuer's common stock on July 26, 2017. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.
F6 The reporting person was granted an option to purchase 75,750 shares of the Issuer's common stock on April 1, 2019. All of the shares underlying such stock option have vested and are exercisable as of the date hereof.